INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 145 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.94 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $263,286 | -61.1% | 14,201 | -76.8% | 0.00% | – |
| Q2 2023 | $677,094 | -42.1% | 61,220 | -29.7% | 0.00% | – |
| Q1 2023 | $1,168,961 | -71.2% | 87,041 | -70.0% | 0.00% | -100.0% |
| Q3 2022 | $4,053,000 | +33.3% | 290,537 | +55.5% | 0.00% | – |
| Q1 2022 | $3,041,000 | -40.3% | 186,866 | -40.3% | 0.00% | -100.0% |
| Q4 2021 | $5,096,000 | +13.5% | 312,795 | +3.5% | 0.00% | +100.0% |
| Q3 2021 | $4,488,000 | -27.7% | 302,206 | -2.8% | 0.00% | -50.0% |
| Q2 2021 | $6,209,000 | +91.7% | 310,876 | +121.5% | 0.00% | +100.0% |
| Q1 2021 | $3,239,000 | -48.7% | 140,336 | -45.1% | 0.00% | -66.7% |
| Q4 2020 | $6,313,000 | -16.0% | 255,569 | +41.0% | 0.00% | -40.0% |
| Q3 2020 | $7,515,000 | -45.7% | 181,261 | -37.2% | 0.01% | -50.0% |
| Q2 2020 | $13,834,000 | +317.3% | 288,770 | +448.5% | 0.01% | +233.3% |
| Q1 2020 | $3,315,000 | -76.7% | 52,645 | -54.2% | 0.00% | -85.0% |
| Q4 2019 | $14,236,000 | +1623.5% | 114,886 | +822.9% | 0.02% | +1900.0% |
| Q3 2019 | $826,000 | -21.4% | 12,448 | -5.7% | 0.00% | 0.0% |
| Q2 2019 | $1,051,000 | -84.7% | 13,200 | -78.5% | 0.00% | -90.9% |
| Q1 2019 | $6,855,000 | +185.3% | 61,280 | +157.0% | 0.01% | +120.0% |
| Q4 2018 | $2,403,000 | -42.6% | 23,841 | -28.1% | 0.01% | -37.5% |
| Q3 2018 | $4,189,000 | +67.4% | 33,151 | +11.1% | 0.01% | +14.3% |
| Q2 2018 | $2,503,000 | +5.6% | 29,830 | -22.6% | 0.01% | +16.7% |
| Q1 2018 | $2,370,000 | -17.0% | 38,529 | -21.1% | 0.01% | -25.0% |
| Q4 2017 | $2,854,000 | -23.4% | 48,860 | -23.9% | 0.01% | -38.5% |
| Q3 2017 | $3,726,000 | -0.6% | 64,196 | +107.2% | 0.01% | 0.0% |
| Q2 2017 | $3,750,000 | -65.8% | 30,984 | -69.3% | 0.01% | -72.3% |
| Q4 2016 | $10,953,000 | +292.0% | 100,816 | +493.8% | 0.05% | +235.7% |
| Q3 2016 | $2,794,000 | +3.9% | 16,978 | -9.9% | 0.01% | +16.7% |
| Q2 2016 | $2,688,000 | +33.3% | 18,844 | +20.0% | 0.01% | +9.1% |
| Q1 2016 | $2,017,000 | +204.7% | 15,700 | +254.2% | 0.01% | +175.0% |
| Q4 2015 | $662,000 | +110.8% | 4,433 | +241.0% | 0.00% | +100.0% |
| Q2 2015 | $314,000 | -97.0% | 1,300 | -96.5% | 0.00% | -97.5% |
| Q1 2015 | $10,450,000 | – | 37,052 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |